Allogene Therapeutics, Inc. (NASDAQ: ALLO) Stock Competitors & Peer Comparison

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while VRTX trades at $477.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas VRTX's P/E ratio is 25.36. In terms of profitability, ALLO's ROE is -0.56%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ALLO is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check VRTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALLO's ROE is -0.56%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ALLO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check VRNA's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while REGN trades at $656.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas REGN's P/E ratio is 14.38. In terms of profitability, ALLO's ROE is -0.56%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALLO is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check REGN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ARGX has a market cap of 57.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ARGX trades at $918.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ARGX's P/E ratio is 82.87. In terms of profitability, ALLO's ROE is -0.56%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ALLO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ARGX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALLO's ROE is -0.56%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALLO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check SGEN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RVMDW trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RVMDW's P/E ratio is -2.29. In terms of profitability, ALLO's ROE is -0.56%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ALLO is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RVMDW's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RVMD trades at $189.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RVMD's P/E ratio is -26.77. In terms of profitability, ALLO's ROE is -0.56%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ALLO is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RVMD's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ALNY has a market cap of 36.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ALNY trades at $271.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ALNY's P/E ratio is 48.97. In terms of profitability, ALLO's ROE is -0.56%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ALLO is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ALNY's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ONC trades at $325.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ONC's P/E ratio is 72.91. In terms of profitability, ALLO's ROE is -0.56%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ALLO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ONC's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ROIV trades at $35.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ROIV's P/E ratio is -35.99. In terms of profitability, ALLO's ROE is -0.56%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ALLO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ROIV's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while INCY trades at $117.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas INCY's P/E ratio is 15.82. In terms of profitability, ALLO's ROE is -0.56%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ALLO is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check INCY's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while INSM trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas INSM's P/E ratio is -18.59. In terms of profitability, ALLO's ROE is -0.56%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ALLO is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check INSM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BNTX trades at $89.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BNTX's P/E ratio is -19.34. In terms of profitability, ALLO's ROE is -0.56%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ALLO is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BNTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while UTHR trades at $528.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas UTHR's P/E ratio is 19.51. In terms of profitability, ALLO's ROE is -0.56%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALLO is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check UTHR's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MRNA trades at $54.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MRNA's P/E ratio is -6.63. In terms of profitability, ALLO's ROE is -0.56%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ALLO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check MRNA's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALLO's ROE is -0.56%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ALLO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BGNE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALLO's ROE is -0.56%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ALLO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check DNA-WT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ALLO's ROE is -0.56%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ALLO is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check GMAB's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while NBIX trades at $175.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas NBIX's P/E ratio is 25.40. In terms of profitability, ALLO's ROE is -0.56%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ALLO is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check NBIX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BBIO trades at $84.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BBIO's P/E ratio is -22.47. In terms of profitability, ALLO's ROE is -0.56%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ALLO is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BBIO's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while JAZZ trades at $253.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas JAZZ's P/E ratio is 19.74. In terms of profitability, ALLO's ROE is -0.56%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ALLO is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check JAZZ's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ASND trades at $253.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ASND's P/E ratio is -104.90. In terms of profitability, ALLO's ROE is -0.56%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ALLO is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ASND's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, EXEL has a market cap of 13.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while EXEL trades at $55.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas EXEL's P/E ratio is 16.58. In terms of profitability, ALLO's ROE is -0.56%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ALLO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check EXEL's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALLO's ROE is -0.56%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALLO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check KRTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MDGL trades at $544.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MDGL's P/E ratio is -42.54. In terms of profitability, ALLO's ROE is -0.56%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ALLO is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check MDGL's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while AXSM trades at $241.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas AXSM's P/E ratio is -62.92. In terms of profitability, ALLO's ROE is -0.56%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ALLO is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check AXSM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ARWR trades at $85.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ARWR's P/E ratio is -39.81. In terms of profitability, ALLO's ROE is -0.56%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ALLO is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ARWR's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BMRN trades at $59.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BMRN's P/E ratio is 28.52. In terms of profitability, ALLO's ROE is -0.56%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ALLO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BMRN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALLO's ROE is -0.56%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALLO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RNAM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while TECH trades at $71.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas TECH's P/E ratio is 36.91. In terms of profitability, ALLO's ROE is -0.56%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ALLO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check TECH's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while SMMT trades at $13.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas SMMT's P/E ratio is -8.54. In terms of profitability, ALLO's ROE is -0.56%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALLO is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check SMMT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CYTK trades at $80.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CYTK's P/E ratio is -13.85. In terms of profitability, ALLO's ROE is -0.56%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ALLO is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CYTK's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while KRYS trades at $335.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas KRYS's P/E ratio is 44.81. In terms of profitability, ALLO's ROE is -0.56%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALLO is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check KRYS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while HALO trades at $81.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas HALO's P/E ratio is 17.73. In terms of profitability, ALLO's ROE is -0.56%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ALLO is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check HALO's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALLO's ROE is -0.56%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALLO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RXDX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while IONS trades at $56.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas IONS's P/E ratio is -32.88. In terms of profitability, ALLO's ROE is -0.56%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ALLO is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check IONS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ABVX trades at $125.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ABVX's P/E ratio is -65.89. In terms of profitability, ALLO's ROE is -0.56%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALLO is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check ABVX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALLO's ROE is -0.56%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALLO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check NUVL's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while KYMR trades at $110.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas KYMR's P/E ratio is -31.32. In terms of profitability, ALLO's ROE is -0.56%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ALLO is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check KYMR's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CRNX trades at $83.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CRNX's P/E ratio is -16.32. In terms of profitability, ALLO's ROE is -0.56%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALLO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CRNX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ALKS trades at $52.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ALKS's P/E ratio is 55.67. In terms of profitability, ALLO's ROE is -0.56%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ALLO is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ALKS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while PTGX trades at $136.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas PTGX's P/E ratio is -75.20. In terms of profitability, ALLO's ROE is -0.56%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ALLO is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check PTGX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALLO's ROE is -0.56%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALLO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check IMGN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while TGTX trades at $56.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas TGTX's P/E ratio is 19.26. In terms of profitability, ALLO's ROE is -0.56%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ALLO is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check TGTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALLO's ROE is -0.56%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALLO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BPMC's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while APGE trades at $134.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas APGE's P/E ratio is -31.01. In terms of profitability, ALLO's ROE is -0.56%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ALLO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check APGE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALLO's ROE is -0.56%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALLO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CERE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while IMVT trades at $39.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas IMVT's P/E ratio is -14.76. In terms of profitability, ALLO's ROE is -0.56%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ALLO is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check IMVT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while PCVX trades at $54.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas PCVX's P/E ratio is -7.94. In terms of profitability, ALLO's ROE is -0.56%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ALLO is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check PCVX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while IBRX trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas IBRX's P/E ratio is -8.35. In terms of profitability, ALLO's ROE is -0.56%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ALLO is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check IBRX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALLO's ROE is -0.56%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALLO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check MTSR's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RYTM trades at $102.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RYTM's P/E ratio is -32.62. In terms of profitability, ALLO's ROE is -0.56%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ALLO is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RYTM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while PRAX trades at $325.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas PRAX's P/E ratio is -24.33. In terms of profitability, ALLO's ROE is -0.56%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ALLO is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check PRAX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALLO's ROE is -0.56%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ALLO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check MRUS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while COGT trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas COGT's P/E ratio is -18.84. In terms of profitability, ALLO's ROE is -0.56%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ALLO is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check COGT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALLO's ROE is -0.56%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALLO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ACLX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ERAS trades at $19.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ERAS's P/E ratio is -20.55. In terms of profitability, ALLO's ROE is -0.56%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ALLO is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ERAS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALLO's ROE is -0.56%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALLO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RETA's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while PTCT trades at $76.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas PTCT's P/E ratio is -32.97. In terms of profitability, ALLO's ROE is -0.56%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ALLO is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check PTCT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALLO's ROE is -0.56%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALLO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CNTA's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while SYRE trades at $102.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas SYRE's P/E ratio is -49.10. In terms of profitability, ALLO's ROE is -0.56%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ALLO is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check SYRE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while BLTE trades at $153.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas BLTE's P/E ratio is -82.01. In terms of profitability, ALLO's ROE is -0.56%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ALLO is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check BLTE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CGON trades at $69.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CGON's P/E ratio is -29.75. In terms of profitability, ALLO's ROE is -0.56%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALLO is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CGON's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while LGND trades at $300.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas LGND's P/E ratio is 36.03. In terms of profitability, ALLO's ROE is -0.56%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ALLO is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check LGND's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while SRRK trades at $47.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas SRRK's P/E ratio is -13.28. In terms of profitability, ALLO's ROE is -0.56%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ALLO is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check SRRK's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MIRM trades at $113.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MIRM's P/E ratio is -8.30. In terms of profitability, ALLO's ROE is -0.56%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ALLO is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check MIRM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALLO's ROE is -0.56%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ALLO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CDTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALLO's ROE is -0.56%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALLO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ABCM's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALLO's ROE is -0.56%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALLO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ISEE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while TVTX trades at $57.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas TVTX's P/E ratio is -260.73. In terms of profitability, ALLO's ROE is -0.56%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ALLO is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check TVTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALLO's ROE is -0.56%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALLO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check APLS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while XENE trades at $65.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas XENE's P/E ratio is -13.92. In terms of profitability, ALLO's ROE is -0.56%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ALLO is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check XENE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALLO's ROE is -0.56%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALLO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check TERN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while DFTX trades at $43.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALLO's ROE is -0.56%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ALLO is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check DFTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MANE trades at $109.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MANE's P/E ratio is -34.92. In terms of profitability, ALLO's ROE is -0.56%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ALLO is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check MANE's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALLO's ROE is -0.56%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALLO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check FOLD's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALLO's ROE is -0.56%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALLO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check AKRO's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CRSP trades at $46.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CRSP's P/E ratio is -9.11. In terms of profitability, ALLO's ROE is -0.56%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ALLO is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CRSP's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALLO's ROE is -0.56%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALLO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ALPN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while EWTX trades at $40.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas EWTX's P/E ratio is -24.60. In terms of profitability, ALLO's ROE is -0.56%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ALLO is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check EWTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CAI trades at $15.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CAI's P/E ratio is -85.37. In terms of profitability, ALLO's ROE is -0.56%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ALLO is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CAI's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while DNTH trades at $103.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas DNTH's P/E ratio is -25.15. In terms of profitability, ALLO's ROE is -0.56%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ALLO is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check DNTH's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ACAD trades at $24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ACAD's P/E ratio is 12.18. In terms of profitability, ALLO's ROE is -0.56%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ALLO is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ACAD's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALLO's ROE is -0.56%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALLO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check OPT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALLO's ROE is -0.56%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALLO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check MRTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while LEGN trades at $22.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas LEGN's P/E ratio is -32.68. In terms of profitability, ALLO's ROE is -0.56%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ALLO is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check LEGN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, DYN has a market cap of 4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while DYN trades at $24.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas DYN's P/E ratio is -7.59. In terms of profitability, ALLO's ROE is -0.56%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ALLO is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check DYN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while VKTX trades at $34.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas VKTX's P/E ratio is -8.40. In terms of profitability, ALLO's ROE is -0.56%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ALLO is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check VKTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CELC trades at $82.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CELC's P/E ratio is -21.18. In terms of profitability, ALLO's ROE is -0.56%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ALLO is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check CELC's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ALLO's ROE is -0.56%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALLO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CPRX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ELVN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ELVN's P/E ratio is -31.71. In terms of profitability, ALLO's ROE is -0.56%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ALLO is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ELVN's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALLO's ROE is -0.56%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALLO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check RYZB's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALLO's ROE is -0.56%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALLO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check CBAY's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while DNLI trades at $23.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas DNLI's P/E ratio is -8.02. In terms of profitability, ALLO's ROE is -0.56%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ALLO is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check DNLI's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while NAMSW trades at $19.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, ALLO's ROE is -0.56%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ALLO is less volatile compared to NAMSW. This indicates lower risk in terms of short-term price fluctuations for ALLO.Check NAMSW's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while ADPT trades at $22.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas ADPT's P/E ratio is -41.24. In terms of profitability, ALLO's ROE is -0.56%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, ALLO is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check ADPT's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALLO's ROE is -0.56%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ALLO is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check SWTX's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while NAMS trades at $29.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas NAMS's P/E ratio is -18.64. In terms of profitability, ALLO's ROE is -0.56%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ALLO is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check NAMS's competition here

Allogene Therapeutics, Inc. (NASDAQ: ALLO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALLO stands at 424.3M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, ALLO is priced at $1.74 on the NASDAQ, while TLX trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALLO currently has a P/E ratio of -2.26, whereas TLX's P/E ratio is -555.43. In terms of profitability, ALLO's ROE is -0.56%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ALLO is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ALLO.Check TLX's competition here